Chardan Capital Maintains Buy on Immunovant, Raises Price Target to $32
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Matthew Barcus maintains a Buy rating on Immunovant (NASDAQ:IMVT) and raises the price target from $21 to $32.
May 23, 2023 | 8:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital maintains a Buy rating on Immunovant and raises the price target from $21 to $32.
Chardan Capital's Buy rating and increased price target for Immunovant (IMVT) indicate a positive outlook for the stock. The raised price target from $21 to $32 suggests that the analyst believes the stock has significant upside potential. This news is likely to have a positive impact on IMVT's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100